Literature DB >> 24486406

Subtypes of irritable bowel syndrome in children and adolescents.

Mariella M Self1, Danita I Czyzewski2, Bruno P Chumpitazi3, Erica M Weidler4, Robert J Shulman4.   

Abstract

BACKGROUND & AIMS: Pharmacologic treatments for irritable bowel syndrome (IBS) and medical management of symptoms are increasingly based on IBS subtype, so it is important to accurately differentiate patients. Few studies have classified subtypes of pediatric IBS, and conclusions have been challenged by methodologic limitations. We performed a prospective study to investigate the distribution of IBS subtypes among children and adolescents based on stool diary information, and compared subtypes according to demographic and pain characteristics.
METHODS: We studied 129 subjects, ages 7 to 18 years (mean age, 11.4 ± 2.8 y; 60.5% female; 69.0% white) who met Pediatric Rome III IBS criteria and were part of larger studies of children with functional gastrointestinal disorders, recruited from primary and tertiary care centers. Children completed daily pain and stool diaries for 2 weeks. Participants were assigned IBS subtypes based on their reported stool information per adult Rome III criteria. IBS subtypes were compared for demographic variables and pain characteristics.
RESULTS: IBS with constipation was the most common subtype of the disorder (58.1% of subjects), whereas mixed IBS was the least common (2.3% of subjects); 34.1% of subjects were unsubtyped IBS and 5.4% had IBS with diarrhea. The groups of different IBS subtypes did not differ significantly by sex, age, ethnicity, or pain characteristics.
CONCLUSIONS: In contrast to adults, in children, IBS with constipation and unsubtyped IBS are the most common subtypes, whereas IBS with diarrhea and mixed IBS are less common. Demographic and pain characteristics cannot distinguish subtypes.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Children; IBS Subtypes; Irritable Bowel Syndrome; Pediatric Functional GI Disorders

Mesh:

Year:  2014        PMID: 24486406      PMCID: PMC4428553          DOI: 10.1016/j.cgh.2014.01.031

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  31 in total

1.  Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation.

Authors:  S A Müller-Lissner; I Fumagalli; K D Bardhan; F Pace; E Pecher; B Nault; P Rüegg
Journal:  Aliment Pharmacol Ther       Date:  2001-10       Impact factor: 8.171

2.  Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.

Authors:  M Camilleri; A R Northcutt; S Kong; G E Dukes; D McSorley; A W Mangel
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

3.  Characteristics of acute pain attacks in patients with irritable bowel syndrome meeting Rome III criteria.

Authors:  Per M Hellström; Yuri A Saito; Peter Bytzer; Jan Tack; Stefan Mueller-Lissner; Lin Chang
Journal:  Am J Gastroenterol       Date:  2011-03-29       Impact factor: 10.864

4.  Discrepancy between recalled and recorded bowel habits in irritable bowel syndrome.

Authors:  M Coletta; L Di Palma; C Tomba; G Basilisco
Journal:  Aliment Pharmacol Ther       Date:  2010-04-02       Impact factor: 8.171

5.  A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator.

Authors:  Douglas A Drossman; Carolyn B Morris; Yuming Hu; Brenda B Toner; Nicholas Diamant; Jane Leserman; Michael Shetzline; Christine Dalton; Shrikant I Bangdiwala
Journal:  Gastroenterology       Date:  2005-03       Impact factor: 22.682

6.  The interpretation of Rome III criteria and method of assessment affect the irritable bowel syndrome classification of children.

Authors:  D I Czyzewski; M M Lane; E M Weidler; A E Williams; P R Swank; R J Shulman
Journal:  Aliment Pharmacol Ther       Date:  2010-12-08       Impact factor: 8.171

7.  A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.

Authors:  M Camilleri; W Y Chey; E A Mayer; A R Northcutt; A Heath; G E Dukes; D McSorley; A M Mangel
Journal:  Arch Intern Med       Date:  2001-07-23

Review 8.  Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome.

Authors:  J Matricon; M Meleine; A Gelot; T Piche; M Dapoigny; E Muller; D Ardid
Journal:  Aliment Pharmacol Ther       Date:  2012-10-15       Impact factor: 8.171

9.  Irritable bowel syndrome subtypes defined by Rome II and Rome III criteria are similar.

Authors:  Spencer D Dorn; Carolyn B Morris; Yuming Hu; Brenda B Toner; Nicholas Diamant; William E Whitehead; Shrikant I Bangdiwala; Douglas A Drossman
Journal:  J Clin Gastroenterol       Date:  2009-03       Impact factor: 3.062

10.  Subtypes and Symptomatology of Irritable Bowel Syndrome in Children and Adolescents: A School-based Survey Using Rome III Criteria.

Authors:  Shaman Rajindrajith; Niranga M Devanarayana
Journal:  J Neurogastroenterol Motil       Date:  2012-07-10       Impact factor: 4.924

View more
  19 in total

1.  Bristol Stool Form Scale reliability and agreement decreases when determining Rome III stool form designations.

Authors:  B P Chumpitazi; M M Self; D I Czyzewski; S Cejka; P R Swank; R J Shulman
Journal:  Neurogastroenterol Motil       Date:  2015-12-21       Impact factor: 3.598

2.  Present state and future challenges in pediatric abdominal pain therapeutics research: Looking beyond the forest.

Authors:  Craig A Friesen; Jennifer V Schurman; Susan M Abdel-Rahman
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

3.  Childhood Irritable Bowel Syndrome Characteristics Are Related to Both Sex and Pubertal Development.

Authors:  Bruno P Chumpitazi; Erica M Weidler; Danita I Czyzewski; Mariella M Self; Margaret Heitkemper; Robert J Shulman
Journal:  J Pediatr       Date:  2016-09-14       Impact factor: 4.406

4.  Lactulose Breath Test Gas Production in Childhood IBS Is Associated With Intestinal Transit and Bowel Movement Frequency.

Authors:  Bruno P Chumpitazi; Erica M Weidler; Robert J Shulman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-04       Impact factor: 2.839

5.  Gastrointestinal symptoms predictors of health-related quality of life in pediatric patients with functional gastrointestinal disorders.

Authors:  James W Varni; Robert J Shulman; Mariella M Self; Samuel Nurko; Miguel Saps; Shehzad A Saeed; Ashish S Patel; Chelsea Vaughan Dark; Cristiane B Bendo; John F Pohl
Journal:  Qual Life Res       Date:  2016-10-14       Impact factor: 4.147

6.  The Prevalence of Hypermobility in Children with Irritable Bowel Syndrome and Functional Abdominal Pain Is Similar to that in Healthy Children.

Authors:  Robert J Shulman; Mariella M Self; Danita I Czyzewski; Jerry Goldberg; Margaret Heitkemper
Journal:  J Pediatr       Date:  2020-05-04       Impact factor: 4.406

7.  Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome.

Authors:  B P Chumpitazi; J L Cope; E B Hollister; C M Tsai; A R McMeans; R A Luna; J Versalovic; R J Shulman
Journal:  Aliment Pharmacol Ther       Date:  2015-06-24       Impact factor: 8.171

8.  Stooling Characteristics in Children With Irritable Bowel Syndrome.

Authors:  Erica M Weidler; Mariella M Self; Danita I Czyzewski; Robert J Shulman; Bruno P Chumpitazi
Journal:  Clin Gastroenterol Hepatol       Date:  2016-08-25       Impact factor: 11.382

Review 9.  The Effects of the Rome IV Criteria on Pediatric Gastrointestinal Practice.

Authors:  Desiree F Baaleman; Carlo Di Lorenzo; Marc A Benninga; Miguel Saps
Journal:  Curr Gastroenterol Rep       Date:  2020-03-19

10.  Evidence of increased fecal granins in children with irritable bowel syndrome and correlates with symptoms.

Authors:  Robert J Shulman; Lena Öhman; Mats Stridsberg; Kevin Cain; Magnus Simrén; Margaret Heitkemper
Journal:  Neurogastroenterol Motil       Date:  2018-10-09       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.